Form 4: MBX Biosciences Director Steven Ryder Acquires Stock Options
SEC Form 4 Filing
Director Steven Ryder of MBX Biosciences acquired stock options for 15,963 shares on September 12, 2024.
Summary
- On September 12, 2024, Steven Ryder, a director of MBX Biosciences, acquired stock options for 15,963 shares.
- The exercise price of these options is $16.
- The options vest over time, with 25% becoming exercisable on September 12, 2025, and the remaining 75% vesting in equal monthly installments over the following 36 months, contingent upon continued service.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't convey any particular positive or negative sentiment about the company's performance or prospects.
Industry Context
This is a standard regulatory filing related to insider transactions. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders, as the value of the options increases if the company's stock price increases.
Key Dates
| Date | Description |
|---|---|
| 09/12/2024 | Date of stock option grant to Steven Ryder. |
| 09/12/2025 | 25% of the stock options vest and become exercisable. |
| 09/11/2034 | Expiration date of the stock options. |
| 09/13/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.